📰 Eric Endicott News
Page 2 - Eric Endicott News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Eric Endicott. Real-time updates on events, politics, business and more.
June 2, 2022
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein
June 2, 2022
Investegate announcements from Prothena Corporation plc, Prothena to Participate in Jefferies Healthcare Conference
May 5, 2022
Investegate announcements from Prothena Corporation plc, Prothena Reports First Quarter 2022 Financial Results and Business Highlights
May 5, 2022
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 millionAdvanced PRX012, a potential best-in-class, subcutaneous
April 28, 2022
Investegate announcements from Prothena Corporation plc, Prothena to Report First Quarter 2022 Financial Results on May 5th
April 28, 2022
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein
April 28, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
April 26, 2022
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer's disease DUBLIN, Ireland, April 26, 2022 (GLOBE
March 28, 2022
Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimers Disease ... | March 28, 2022
March 28, 2022
Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer's disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA)